Keywords
chromone derivatives
vascular endothelium
aggregation
coagulation
rats
Full Text
Abstract
Introduction. Antithrombotic potential disturbance of vascular endothelium is one of the leading pathogenetic mechanisms for the development of muscular dysfunction — a pathological condition with a high risk of developing complications of the cardiovascular, respiratory, endocrine and immune systems.
Aim: to study the effect of chromone-3-aldehyde derivative (X3AOAc) on antithrombotic potential of the vascular endothelium under conditions of muscle dysfunction in the experiment.
Materials and methods. The study was performed on male mices line BALB/c. Muscle dysfunction was reproduced by the modified test protocol «forced swimming with a 20% load» (duration of the experiment was 28 days). Mexidol (100 mg/kg), metaprot (14.3 mg/kg) and mildronate (100 mg/kg) were used as comparison drugs. The test compound X3AOAc was administered intra- gastrally (20 mg/kg) once a day during the experiment (comparison drugs were administered by the same schedule). Antithrom- botic endothelial function was assessed by changes of platelet aggregation (degree and rate) and parameters of coagulation hemostasis: activated partial thromboplastin time, thrombin time, fibrinogen content, von Willebrand factor and antithrombin III (AT-III) system activity.
Results. Compound X3AOAc reduced the degree and rate of platelet aggregation by 2.1 times (p<0.05) and of 71.6% (p<0.05), respectively, in comparison with animals without pharmacological support. Furthermore, normalization of coagulation hemostasis component and restoration of AT-III system activity were noted under X3AOAc administration to rats.
Conclusion. The use of new chromone-3-aldehyde derivative under conditions of muscle dysfunction help to restore the antithrombotic potential of vascular endothelium. At the same time, the pharmacological effect of the test compound X3AOAc was comparable to that of mexidol and was superior to metaprotal and mildronate effects.
REFERENCES
1. Potvin J.R., Fuglevand A.J. A motor unit-based model of mus- cle fatigue. PLoS Comput Biol. 2017;13(6): e1005581. DOI: 10.1371/journal.pcbi.1005581. PMID: 28574981.
2. Río-Rodríguez D., Iglesias-Soler E., Fernández Del Olmo M. Set configuration in resistance exercise: muscle fatigue and cardiovas- cular effects. PLoS One. 2016;11(3): e0151163. DOI: 10.1371/jour- nal.pone.0151163. PMID: 26982500.
3. Gałązka-Franta A., Jura-Szołtys E., Smółka W., Gawlik R. Upper respiratory tract diseases in athletes in different sports disciplines. J Hum Kinet. 2016;53:99–106. DOI: 10.1515/hukin-2016–0014. PMID: 28149415.
4. Silverman M.N., Heim C.M., Nater U.M. et al. Neuroendocrine and immune contributors to fatigue. PM R. 2010;2(5):338–46. DOI: 10.1016/j.pmrj.2010.04.008. PMID: 28149415.
5. Barreiro E., Gea J. Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmo- nary disease. Chron Respir Dis. 2016;13(3):297–311. DOI: 10.1177/1479972316642366. PMID: 27056059.
6. Tidball J.G., Wehling-Henricks M. Nitric oxide synthase defi- ciency and the pathophysiology of muscular dystrophy. J Physiol. 2014;592(21):4627–38. DOI: 10.1113/jphysiol.2014.274878. PMID: 25194047.
7. Aird W.C. Phenotypic heterogeneity of the endothelium: I. Struc- ture, function, and mechanisms. Circ Res. 2007;100(2):158–73. DOI: 10.1161/01.RES.0000255691.76142.4a. PMID: 17272818.
8. Verma S., Buchanan M.R., Anderson T.J. Endothelial func- tion testing as a biomarker of vascular disease. Circulation. 2003;108(17):2054–59. DOI: 10.1161/01.CIR.0000089191.72957. ED. PMID: 14581384.
9. Deguchi H., Sinha R.K., Marchese P. et al. Prothrombotic skele- tal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. Blood. 2016;128(14):1870–8. DOI: 10.1182/blood-2016-03-707679. PMID: 27421960.
10. Voronkov A.V., Pozdnyakov D.I., Nigaryan S.A. et al. Evaluation of the mitochondria respirometric function in the conditions of pa- thologies of various genesis. [Ocenka respirometricheskoj funkcii mitohondrij v usloviyah patologij razlichnogo geneza]. Farmaciya i farmakologiya. 2019;7(1):20–31 (in Russ.). DOI: 10.19163/2307- 9266-2019-7-1-20-31.
11. Baulin S.I., Rogacheva S.M., Afanasyeva S.V. Effect of drugs on exercise performance. [Izuchenie vliyaniya farmacevticheskih preparatov na fizicheskuyu rabotosposobnost’]. Byulleten’ eksperimental’noj biologii i mediciny. 2013;155(5):586–9 (in Russ.).
12. Voronina T.A., Kapitsa, I.G., Ivanova E.A. A comparative study of the effects of mexidolum and mildronatum on the physical perfor- mance of experimental animals. [Cravnitel’noe issledovanie vliya- niya meksidola i mildronata na fizicheskuyu rabotosposobnost’ v eksperimente]. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2017;117 (4):71–4 (in Russ.).
13. Gabbasov Z.A., Popov E.G., Gavrilov I. Yu. et al. New highly sensitive method for analyzing platelet aggregation. [Novyj vysokochuvstvitel’nyj metod analiza agregacii trombocitov]. Laboratornoe delo. 1989;(10):15–8 (in Russ.).
14. Voronkov A.V., Pozdnyakov D.I. Disturbances of antithrombotic vascular endothelial function and some plasma hemostatic pa- rameters associated with focal cerebral ischemia and their cor- rection by 4-hydroxy-3,5-ditertbutyl cinnamic acid. [Narushe- nie antitromboticheskoj funkcii endoteliya sosudov i nekotoryh parametrov plazmennogo gemostaza na fone fokal’noj ishemii go- lovnogo mozga i ih korrekciya 4-gidroksi-3,5-ditretbutil korichnoj kislotoj]. Tromboz, gemostaz i reologiya. 2017;(2):73–8 (in Russ.).
15. Pozdnyakov D.I., Voronkov A.V., Rybalko A.E. et al. Chro- mone-3-aldehyde derivatives–sirtuin 2 inhibitors for correction of muscular dysfunction. Current Issues in Pharmacy and Medical Sciences. 2019;32(1):45–50. DOI: 10.2478/cipms-2019–0010. 16. Liu F.C., Liao C.H., Chang Y.W. et al. A new insight of antiplatelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase. Biochem Pharmacol. 2009;77:1364–73. DOI: 10.1016/j.bcp.2009.01.011. PMID: 19426675.
17. Kumari S., Chaurasia S.N., Nayak M.K. et al. Sirtuin inhibition induces apoptosis-like changes in platelets and thrombocytopenia. J Biol Chem. 2015;290(19):12290–9. DOI: 10.1074/jbc. M114.615948. PMID: 25829495.
18. Wu Z.Y., Li H., Tang Y.J. Effect of simvastatin on the SIRT2/NF-κB pathway in rats with acute pulmonary embolism. Pharm Biol. 2018;56(1):511–18. DOI: 10.1080/13880209.2018.1508239. PMID: 31070532.